Instructional Video11:40
Crash Course

The Handmaid's Tale, Part 2: Crash Course Literature 404

12th - Higher Ed
This week, John Green continues to teach you about Margaret Atwood's speculative fiction, The Handmaid's Tale. In this installment, we're looking at Atwood's desire to tell a story from a female point of view, and what exactly it means...
Instructional Video5:02
TED-Ed

TED-ED: Why should you read "The Handmaid's Tale"? - Naomi R. Mercer

Pre-K - Higher Ed
Margaret Atwood's speculative fiction masterpiece The Handmaid's Tale explores the consequences of complacency and how power can be wielded unfairly. Atwood's chilling vision of a dystopian regime has captured readers' imaginations since...
Instructional Video5:14
Healthcare Triage

Old Drugs, New Tricks: Remdesivir and Other Potential Treatments for COVID19

Higher Ed
As the coronavirus and COVID19 pandemic continues, researchers are investigating some older drugs that may be viable treatments for the disease. One drug of interest is remdesivir, a decade old drug intended to treat hepatitis. It was...
Instructional Video8:41
TLDR News

Trials Underway for Coronavirus Treatments & Vaccines: Are We Getting Close? - TLDR News

12th - Higher Ed
Trials Underway for Coronavirus Treatments & Vaccines: Are We Getting Close? - TLDR News
Instructional Video1:13
Next Animation Studio

Explainer: What is Remdesivir and how does it treat COVID-19

12th - Higher Ed
Gilead’s remdesivir is an antiviral nucleoside analogue that disrupts a virus’s ability to replicate its genome.
News Clip0:58
Curated Video

FDA Green Lights Potential Coronavirus Recovery Drug

Higher Ed
The FDA approved emergency use its anti-viral drug for further testing on those with severe cases requiring them to be on breathing support.
News Clip2:05
Bloomberg

Gilead to Buy Kite for $11.9 Billion in Cancer Megadeal

Higher Ed
Aug.28 -- Bloomberg’s Taylor Riggs discusses a Gilead Sciences-Kite Pharma deal. She speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets."
News Clip2:57
Bloomberg

China Seals Off County of 400,000 to Stem Beijing Cluster 

Higher Ed
Jun.30 -- China put 400,000 residents of a northern county under lockdown over the weekend after at least a dozen coronavirus cases associated with the Beijing outbreak were reported there. Bloomberg's Selina Wang has the story.
News Clip1:08
Curated Video

Official: U.S. Supply Of COVID-19 Drug Could Run Out Soon

Higher Ed
An official from the Department of Health and Human Services says the last shipment of the COVID-19 treatment drug will be sent the week of June 29.
News Clip1:44
Curated Video

Gilead Shares Early Results Of Remdesivir Trial In COVID-19 Patients

Higher Ed
Patients given remdesivir for five days had improved symptoms compared to those who were only given standard care.
News Clip2:44
Bloomberg

50% Chance Gilead's Coronavirus Drug Will Work: RBC Analyst

Higher Ed
Brian Abrahams, RBC Capital Markets co-head of biotechnology research, discusses his call for the performance of Gilead Sciences's��experimental coronavirus therapy on "Bloomberg Markets: The Close." (Source: Bloomberg)
News Clip2:51
Bloomberg

AstraZeneca Is Said to Approach Gilead About Potential Merger

Higher Ed
Jun.07 -- AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter. Su Keenan reports on "Bloomberg Daybreak: Australia."
News Clip3:38
Bloomberg

The Top Ten Stocks for Dec. 26

Higher Ed
Dec. 26 -- Bloomberg's Trish Regan, Cory Johnson and Pimm Fox report on todays top ten stocks.
News Clip2:28
Bloomberg

Why Express Scripts Chose AbbVie Over Gilead

Higher Ed
Dec. 22 -- Bloomberg's Drew Armstrong discusses pharmaceuticals and the health care industry with Mia Saini on Bottom Line. (Source: Bloomberg)
News Clip1:46
Bloomberg

Existing Home Sales Fall 6.1% in November

Higher Ed
Dec. 22 -- Bloomberg's Olivia Sterns reports on todays top news stories on Money Clip.
News Clip3:22
Bloomberg

Options Insight: How to Play Gilead Sciences

Higher Ed
July 22 -- Scott Bauer, senior market strategist at Trading Advantage, discusses the U.S. markets and his options play for Gilead Sciences. He speaks with Bloomberg's Julie Hyman on "Bloomberg Markets."
News Clip2:31
Bloomberg

Market Wrap 10/31: October S&P, Energy, Gilead

Higher Ed
Oct.31 -- Bloomberg market reporters take a deep dive into all of the action today.
News Clip2:47
Bloomberg

Bloomberg Market Wrap 4/10: Amerisource, Macy's, Health Care

Higher Ed
Apr.10 -- Bloomberg market reporters take a deep dive into all of today's action.